Quarterly Consolidated Statement Of Cash Flows

RaQualia Pharma Inc. - Filing #7269486

Concept 2024-01-01 to
2024-12-31
As at
2024-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
As at
2022-12-31
Quarterly consolidated statement of cash flows
Statement of cash flows
Cash flows from operating activities
Subtotal
311,695,000 JPY
-595,528,000 JPY
Interest and dividends received
13,654,000 JPY
10,110,000 JPY
Interest paid
-42,643,000 JPY
-6,760,000 JPY
Income taxes paid
-131,646,000 JPY
-121,631,000 JPY
Net cash provided by (used in) operating activities
180,945,000 JPY
-718,596,000 JPY
Cash flows from investing activities
Purchase of property, plant and equipment
-96,707,000 JPY
-204,475,000 JPY
Purchase of investment securities
JPY
-160,000,000 JPY
Proceeds from sale of investment securities
258,563,000 JPY
JPY
Purchase of shares of subsidiaries resulting in change in scope of consolidation
-3,879,637,000 JPY
JPY
Other, net
-28,635,000 JPY
-3,168,000 JPY
Net cash provided by (used in) investing activities
-3,665,610,000 JPY
-135,373,000 JPY
Cash flows from financing activities
Proceeds from short-term borrowings
400,000,000 JPY
JPY
Repayments of short-term borrowings
-400,000,000 JPY
JPY
Proceeds from long-term borrowings
3,357,800,000 JPY
50,000,000 JPY
Repayments of long-term borrowings
-387,620,000 JPY
-10,120,000 JPY
Proceeds from issuance of shares
79,826,000 JPY
782,614,000 JPY
Purchase of treasury shares
-80,000 JPY
0 JPY
Net cash provided by (used in) financing activities
2,982,105,000 JPY
793,450,000 JPY
Effect of exchange rate change on cash and cash equivalents
-20,251,000 JPY
45,953,000 JPY
Net increase (decrease) in cash and cash equivalents
-522,809,000 JPY
-14,565,000 JPY
Cash and cash equivalents
3,141,929,000 JPY
3,664,738,000 JPY
3,679,304,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.